Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03718884 · ClinicalTrials.gov registry record · Phase 1
A Study of Mirikizumab in Participants With Plaque Psoriasis
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT03718884 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 29 participants.
The verdict
NCT03718884, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after multiple doses of mirikizumab. The study will last about 23 weeks for each participant. Screening must be completed within 4 weeks prior to study start.
Interventions
- DRUG Mirikizumab
- DRUG Drug Cocktail
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2018-10-23 |
| Est. Completion | 2019-10-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03718884
The ClinicalTrials.gov registry entry for NCT03718884 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Mirikizumab is the first listed.
NCT03718884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03718884 about?
NCT03718884 is a clinical study titled "A Study of Mirikizumab in Participants With Plaque Psoriasis". This study is known as a "drug interaction study." The purpose is to learn how commonly used drugs or substances (midazolam, warfarin, dextromethorphan, omeprazole, and caffeine) and their breakdown products get into the bloodstream after taking a "cocktail" (combination) of them before and after mu...
What is the current status of trial NCT03718884?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2018-10-23. Estimated completion is 2019-10-28.
What interventions are being tested in trial NCT03718884?
The interventions under investigation include: Mirikizumab (DRUG), Drug Cocktail (DRUG).
Who is sponsoring clinical trial NCT03718884?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.